HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales

This article was originally published in The Rose Sheet

Executive Summary

Proponents say the herbal ingredient extracted from a plant in the coffee family and available in powders, capsules or pills and beverages has been used in the US since long before the October 1994 grandfather date for ingredients to be eligible for use in supplements without being notified to FDA as new. But FDA wants NDI notifications, and the four submitted so far have been incomplete or did not show safety for intended use in a supplement.

Advertisement

Related Content

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules
Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA
Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations
FDA Waves Stop Sign At Kratom Product Launch After Failed NDI Notification
FDA's Kratom Campaign Turns To Firms Destroying Inventory, Recalling Products
FDA's Opioid Label For Kratom Called Misbranding By Marketers
FDA Turns Kratom's Future In US Dietary Supplement Market Into History

Topics

Advertisement
UsernamePublicRestriction

Register

RS121787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel